📈 GH SECRETAGOGUE BLEND

CJC-1295 DAC + Ipamorelin Blend

This blend pairs CJC-1295 with Drug Affinity Complex (DAC) — a long-acting GHRH analog with ~6–8 day half-life — with Ipamorelin, the most selective GHS-R agonist. Unlike CJC-No DAC blends, the DAC version enables true once-weekly dosing for the GHRH component while Ipamorelin is dosed daily for pulsatile GH stimulation.

⚡ QUICKSTART HIGHLIGHTS

CJC-1295 DAC DOSE

1–2 mg once weekly

IPAMORELIN DOSE

200–300 mcg once daily

ROUTE

Subcutaneous

CYCLE

8–16 weeks

Dosing & Reconstitution Guide

Vial Options

Vial Format	CJC-DAC	Ipamorelin	BAC Water	Concentration	mcg per Unit
7 mg combo	2 mg	5 mg	2.0 mL	3.5 mg/mL total	35 mcg total
10 mg combo	5 mg	5 mg	2.0 mL	5.0 mg/mL total	50 mcg total

Key distinction: Because CJC-DAC has a 6–8 day half-life, it only needs to be injected once weekly. Ipamorelin is still dosed daily for pulsatile GH release. These are often supplied as two separate vials rather than a pre-mixed blend.

Weekly Protocol

Injection	Peptide	Dose	Units	Timing
Monday (weekly)	CJC-1295 DAC	1–2 mg	varies by conc.	Morning
Daily (Mon–Sun)	Ipamorelin	200–300 mcg	varies by conc.	Bedtime, fasted

Reconstitution Steps

Wipe the vial stopper and BAC water vial with alcohol; let dry.
Draw 2.0 mL of bacteriostatic water into a sterile syringe.
Inject slowly down the inside glass wall of the blend vial. Do not aim at the powder.
Gently swirl until fully dissolved. Do not shake.
Label with reconstitution date. Refrigerate at 2–8°C; use within the window specified above.

How This Works

CJC-1295 with DAC (Drug Affinity Complex) uses a maleimido-propionic acid (MPA) modification that reacts covalently with lysine-rich albumin in the bloodstream, dramatically extending half-life from ~30 minutes (no-DAC version) to approximately 6–8 days. This means a single weekly injection maintains elevated GHRH signaling throughout the week, providing a steady 'tidal' GHRH background rather than a pulse.

Ipamorelin, dosed daily, provides the ghrelin receptor (GHS-R1a) stimulation component — producing discrete GH pulses with the highest receptor selectivity of any GHRP (no cortisol, prolactin, or ACTH elevation at therapeutic doses). The combination of sustained GHRH background (CJC-DAC weekly) plus daily ghrelin receptor pulses (Ipamorelin) provides complementary synergistic GH stimulation.

Potential Benefits & Side Effects

Potential Benefits

CJC-1295 DAC: once-weekly convenience — no daily GHRH injections required.
Ipamorelin: cleanest GHRP — GH stimulation without cortisol/ACTH/prolactin elevation.
Synergistic: GHRH amplifies GH pulse amplitude; GHRP increases GH pulse frequency.
Sustained GHRH background may support IGF-1 elevation across the week.
Well-tolerated — ipamorelin's selectivity minimizes side effects.
Long track record in research community.

Side Effect Profile

Mild fluid retention during first 2–4 weeks (GH-mediated).
Possible mild morning grogginess (GH activity during sleep).
Injection-site reactions.
CJC-DAC: some report decreased GH pulsatility with continuous use vs cycling.
WADA prohibited — all GH secretagogues.
Avoid if active malignancy or diabetic retinopathy.

Storage Instructions

State	Temperature	Duration
Lyophilized	−20°C (−4°F)	−20°C, up to 24 months
Reconstituted	2–8°C	Up to 14 days

⚠ Research Use Only: WADA prohibited. CJC-DAC produces sustained rather than pulsatile GHRH stimulation — different physiology from no-DAC version. Cycle 8–16 weeks then 4–8 week break.

References

Teichman SL et al. 'Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295' — J Clin Endocrinol Metab, 2006 View source ↗

Raun K et al. 'Ipamorelin, the first selective growth hormone secretagogue' — Eur J Endocrinol, 1998 View source ↗